MedTrace Logo

Edoxaban and Frailty in Senior Individuals

NCT03524924 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2022-08-10

No results posted yet for this study

Summary

Edoxaban, has shown in clinical registration trials a significant reduction of major bleeding compared to warfarin, especially in elderly patients. Efficacy and safety of edoxaban will be assessed in a cohort of very elderly patients (≥80 years of age) with NVAF. A secondary analysis will correlate outcomes with frailty defined according to SHARE-FI (not-frail, pre-frail or frail).

Conditions

Sponsors & Collaborators

  • University of Padova

    lead OTHER

Principal Investigators

  • Vittorio Pengo, Prof · Padua University Hospital

Eligibility

Min Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-07
Primary Completion
2021-01-14
Completion
2021-03-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03524924 on ClinicalTrials.gov